[Home ] [Archive]   [ فارسی ]  
:: Main :: About us :: Current Issue :: Archive :: Search :: Submit :: Contact ::
Main Menu
Home::
Journal Information::
About the Journal
Editorial Board
Advisory Board
Aims & Scope
Journal News
Articles archive::
All Issues
Current Issue
Articles in press
For Authors::
Submission Instruction
For Reviewers::
Reviewers Section
Subscription::
Subscription Form
News& Events::
Journal News
Contact us::
Contact Information
Contact us
Site Facilities::
Site map
Search contents
Top 10 contents
Inform others
Ethics & Permissions::
::
Search in website

Advanced Search
..
Receive site information
Enter your Email in the following box to receive the site news and information.
..
Indexing
                        
..
:: Volume 21, Issue 1 (Spring 2024) ::
Sci J Iran Blood Transfus Organ 2024, 21(1): 21-32 Back to browse issues page
Comparison of combined chelation therapy effects (deferoxamine-deferiprone, deferoxamine-deferasirox) with Deferoxamine and Deferasirox in beta-thalassemia major in Yasuj
P. Etemad far , A. Azizi , J.M. Malekzadeh , M. Saghazadeh , O.S. Esmaeili , M. Parsian , F. Rad
Keywords: Key words: beta-Thalassemia Major, Iron Chelating Agents, Deferoxamine, Deferasirox, Drug Therapy, Combination ​​​​​​​
Full-Text [PDF 588 kb]   (67 Downloads)     |   Abstract (HTML)  (183 Views)
Type of Study: Research | Subject: Hematology
Published: 2024/03/29
Full-Text:   (28 Views)
    References:
  1. Ali S, Mumtaz S, Shakir HA, Khan M, Tahir HM, Mumtaz S, et al. Current status of beta‐thalassemia and its treatment strategies. Mol Genet Genomic Med 2021; 9(12): e1788.
  2. Tanno T, Bhanu NV, Oneal PA, Goh SH, Staker P, Lee YT, et al. High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat Med 2007; 13(9): 1096-101.
  3. D'angelo G. Role of hepcidin in the pathophysiology and diagnosis of anemia. Blood Res 2013; 48(1): 10.
  4. Maggio A, Kattamis A, Felisi M, Reggiardo G, El-Beshlawy A, Bejaoui M, et al. Evaluation of the efficacy and safety of deferiprone compared with deferasirox in paediatric patients with transfusion-dependent haemoglobinopathies (DEEP-2): a multicentre, randomised, open-label, non-inferiority, phase 3 trial. Lancet Haematol 2020; 7(6): e469-e78.
  5. Olivieri NF, Sabouhanian A, Gallie BL. Single-center retrospective study of the effectiveness and toxicity of the oral iron chelating drugs deferiprone and deferasirox. PLoS One 2019; 14(2): e0211942.
  6. Mirbehbahani N, Vaseghi G, Rashidbaghan A, Vakili MA, Jahazi A. Comparison of Magnetic Resonance Imaging T2 Results in Beta-Thalassemia Patients Treated by Deferasirox or Combination of Deferoxamine and Deferiprone. Iran J Pediatr Hematol Oncol 2020; 10(4): 241-9.
  7. Abbasi U, Abbina S, Gill A, Takuechi LE, Kizhakkedathu JN. Role of iron in the molecular pathogenesis of diseases and therapeutic opportunities. ACS Chemical Biology 2021; 16(6): 945-72.
  8. Morales NP, Rodrat S, Piromkraipak P, Yamanont P, Paiboonsukwong K, Fucharoen S. Iron chelation therapy with deferiprone improves oxidative status and red blood cell quality and reduces redox-active iron in β-thalassemia/hemoglobin E patients. Biomed Pharmacother 2022; 145: 112381.
  9. Kontoghiorghes GJ, Kleanthous M, Kontoghiorghe CN. The history of deferiprone (L1) and the paradigm of the complete treatment of iron overload in thalassaemia. Mediterr J Hematol Infect Dis 2020; 12: e2020011.
  10. Trachtenberg F, Vichinsky E, Haines D, Pakbaz Z, Mednick L, Sobota A, et al. Iron chelation adherence to deferoxamine and deferasirox in thalassemia. Am J Hematol 2011; 86(5): 433.
  11. Origa R, Bina P, Agus A, Crobu G,  Defraia E, Dessì C, et al. Combined therapy with deferiprone and desferrioxamine in thalassemia major. Haematologica 2005; 90(10): 1309-14.
  12. Kontoghiorghes GJ, Neocleous K, Kolnagou A. Benefits and risks of deferiprone in iron overload in Thalassaemia and other conditions: comparison of epidemiological and therapeutic aspects with deferoxamine. Drug Safety 2003; 26: 553-84.
  13. Elalfy MS, Adly AM, Wali Y, Tony S, Samir A, Elhenawy YI. Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patients. Eur J Haematol 2015; 95(5): 411-20.
  14. Takpradit C, Viprakasit V, Narkbunnam N, Vathana N, Phuakpet K, Pongtanakul B, et al. Using of deferasirox and deferoxamine in refractory iron overload thalassemia. Pediatr Int 2021; 63(4): 404-9.
  15. Zargari A, Wu S, Greenway A, Cheng K, Kaplan Z. Effects of dual chelation therapy with deferasirox and deferoxamine in patients with beta thalassaemia major. Vox Sang 2022; 117(5): 733-7.
  16. Chahkandi T, Kazemi T, Jalili A, Ghaderi F. Evaluation of cardiac function in patients with major beta thalassemia in Birjand. Sci J Iran Blood Transfus Organ 2013; 10(1): 86-92. [Article in Farsi]
  17. Reddy PS, Locke M, Badawy SM. A systematic review of adherence to iron chelation therapy among children and adolescents with thalassemia. Ann Med 2022; 54(1): 326-42.
  18. Origa R, Cinus M, Pilia MP, Gianesin B, Zappu A, Orecchia V, et al. Safety and Efficacy of the New Combination Iron Chelation Regimens in Patients with Transfusion-Dependent Thalassemia and Severe Iron Overload. J Clin Med 2022; 11(7): 2010.
  19. Yusuf S, Herdata HN, Edward ED, Khairunnisa K. Comparison of oral iron chelators in the management of transfusion-dependent β-thalassemia major based on serum ferritin and liver enzymes. F1000Research 2023; 12(154): 154.
  20. Rafati M, Karami H, Lashtoo-Aghaee B, Lashtoo-Aghaee B, Dabirian M, Avan R. Two trade names of deferasirox (Osveral® and Exjade®) in reduction of iron overload parameters in major beta-thalassemia patients: A randomized open labeled clinical trial. Caspian J Intern Med 2022; 13(1): 61-9.
  21. Karami H, Kosaryan M, Abolghasemi H, Rashidighader F, Vahidshahi K, Dabirian M, et al. Deferiprone plus deferoxamine versus deferoxamine iron chalation in beta thalassemia major. Sci J Iran Blood Transfus Organ 2011; 4(7): 227-34. [Article in Farsi]
  22. Moradveisi B, Taghizadeh Sarvestani R, Ghaderi E, Kompany F. Comparison of the heart and liver iron deposition status in Major β Thalassemia patients treated with two iron chelation drugs of “Deferoxamine and Deferasiroxon” using MRI T2* technique. Sci J Iran Blood Transfus Organ 2015; 12(1): 55-62. [Article in Farsi]
  23. Eshghi P. Complications of combined treatment with deferiprone and desferrioxamine in thalassemic patients. Iran J Med Sci 2007; 32(1): 40-4.
  24. Hashemi M, Khosravi S. Determining the efficacy of Deferiprone (L1) on decreasing ferritin levels of Thalassemia patients in Arak. J Arak Univ Med Sci 2008; 11(1): 109-16. [Article in Farsi]
  25. Vichinsky E, Onyekwere O, Porter J, Swerdlow P, Eckman J, Lane P,  et al. A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Br J Haematol 2007; 136(3): 501-8.
  26. Ghanavat M, Reisi N. The Effect of Combination Iron Chelating Agents on Reducing the Severity Grading of Heart and Liver Iron Overload in β-Thalassemia Patients. Iran J Pediatr Hematol Oncol 2019; 9(4): 244-52.
  27. Azarkeivan A, Shaeigan M, Eslami MS, Ghazizadeh S, Oshidari A, Narenjian AR. Evaluation of gastric side effects of new form of Deferiprone,(L1; Enteric coated) in Thalassemia major patients. Sci J Iran Blood Transfus Organ 2016; 13(3): 163-9. [Article in Farsi]




Sci J Iran Blood Transfus Organ 2024;21 (1): 21-32
Original Article
 
 Comparison of combined chelation therapy effects (deferoxamine-deferiprone, deferoxamine-deferasirox) with Deferoxamine and Deferasirox in beta-thalassemia major
in Yasuj

Etemadfar P.1, Azizi A.2, Malekzadeh J.M.3, Saghazadeh M.4, Esmaieli O.S.5,
Parsian M.2, Rad F.2

1Faculty of Medicine, Yasuj University of Medical Sciences, Yasuj, Iran
2Cellular and Molecular Research Center, Yasuj University of Medical Sciences, Yasuj, Iran
3School of Health and Nutrition Sciences, Yasuj University of Medical Sciences, Yasuj, Iran
4Faculty of basic sciences, Qom Branch, Islamic Azad University, Qom, Iran
5Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran


Abstract
Background and Objectives
Chelation therapy is essential for beta-thalassemia major. This study aims to determine the complications clinical and laboratory symptoms of monotherapy and combined treatment of iron chelators in beta-thalassemia major patients in Yasuj.

Materials and Methods
In this cross-sectional-descriptive-analytical study, 103 patients with beta-thalassemia major in Yasuj city were evaluated during 2021-2022. After collecting the demographic, clinical and laboratory information of the patients, the results were reported as mean ± standard deviation and percentage. The degree of statistical differences between ratios was calculated using the Kruskal-Wallis test.

Results
The average age of our patients was reported to be 24.74 ± 8.34 years. 54.4% (n = 56) of the study patients were men and 45.6% (n = 47) were women. The results of the present study showed that there was a statistically significant difference in mean ferritin among different study groups (p = 0.028). Patients treated with deferoxamine showed the highest mean serum ferritin (5925.5 ± 3397ng%) and patients who took deferoxamine together with deferiprone or deferasirox had a lower mean ferritin compared to deferoxamine alone  (3348 ± 2560, 4269 ± 3322 ng%), respectively. Also, the present study showed that after taking iron removers, 47.6% of patients (n = 49) had no clinical complications and 52.4% (n = 54) had at least one complication.

Conclusions 
Our results showed that Deferoxamine can have a great effect in reducing iron deposition and serum ferritin levels in combination with oral drugs.

Key words: beta-Thalassemia Major, Iron Chelating Agents, Deferoxamine, Deferasirox, Drug Therapy،Combination

Received:  26 Sep 2023
Accepted: 28 Jan 2024



Correspondence: Rad F., PhD of Hematology & Blood Banking. Associate Professor of  Cellular and Molecular Research Center, Yasuj University of Medical Sciences.
Postal Code: 7591741417, Yasuj, Iran. Tel: (+9874) 33230290; Fax: (+9874) 33230290
E-mail: fariba.rad89@gmail.com
 
Send email to the article author

Add your comments about this article
Your username or Email:

CAPTCHA

XML   Persian Abstract   Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Etemad far P, Azizi A, Malekzadeh J, Saghazadeh M, Esmaeili O, Parsian M et al . Comparison of combined chelation therapy effects (deferoxamine-deferiprone, deferoxamine-deferasirox) with Deferoxamine and Deferasirox in beta-thalassemia major in Yasuj. Sci J Iran Blood Transfus Organ 2024; 21 (1) :21-32
URL: http://bloodjournal.ir/article-1-1511-en.html
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 21, Issue 1 (Spring 2024) Back to browse issues page
فصلنامه پژوهشی خون Scientific Journal of Iran Blood Transfus Organ
The Scientific Journal of Iranian Blood Transfusion Organization - Copyright 2006 by IBTO
Persian site map - English site map - Created in 0.05 seconds with 39 queries by YEKTAWEB 4645